ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Bronchopulmonary Dysplasia - A Pipeline Analysis Report| Technavio

May 14, 2018 GMT

LONDON--(BUSINESS WIRE)--May 14, 2018--Technavio presents its latest pipeline analysis report on the bronchopulmonary dysplasia market. The report offers an exhaustive analysis of the pipeline molecules under investigation within the defined data collection period to treat bronchopulmonary dysplasia.

ADVERTISEMENT

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514005756/en/

Technavio has published a new pipeline analysis report on the global bronchopulmonary dysplasia market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

The report will also provide an analysis of the various factors that are expected to play an essential role in the growth of the market during the forecast period, including regulatory framework, drug development strategies, recruitment strategies, and key companies.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

ADVERTISEMENT

Save more with Technavio. Buy2 reports and get the third for FREE: View all Technavio’s current offers

Bronchopulmonary dysplasia - market at a glance

Bronchopulmonary dysplasia is a chronic respiratory infection, which regularly happens in low birth weight or premature babies or newborn babies with intense respiratory distress syndrome who have provided with supplement oxygen or kept in a breathing machine (machine ventilation) for a long time. Bronchopulmonary dysplasia can also occur in older infants who experience abnormal lung development or in infants who have an infection before birth (antenatal infection) or placental abnormalities such as pre-eclampsia.

According to a senior analyst at Technavio for infectious and rare diseases, “Some premature infants get affected with respiratory distress syndrome, which is a breathing disorder, immediately after birth. It is characterized by rapid, shallow breathing and leads to the need for oxygen and respiratory support in the first few days of life. The infants who are affected by bronchopulmonary dysplasia may also feel shortness of breath, flaring of nostrils while inhaling, a chronic cough, and staining of the skin because of low levels of oxygen in the blood.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Bronchopulmonary dysplasia - segmentation analysis

This market research report segments the bronchopulmonary dysplasia market based on therapies employed that includes monotherapy, RoA (intratracheal, intravenous, inhaled, and oral), therapeutic modalities (small molecules and biomolecule), targets for drugs under development (IGF-1 and IGFBP-3, SCGB1A1, thioredoxin, CXCR1/2, and unspecified), MoA (protein replacement, cell replacement, IGF-1 receptor, thioredoxin mimetic, CXCR1/2 antagonist, and undisclosed), and recruitment status (not yet recruiting, completed, active not recruiting, and unspecified).

Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, all the molecules that are being invested are monotherapy.

Intratracheal refers to the introduction of drugs into the trachea. It is an alternative to inhalation. In the current pipeline, 49% of the total therapeutics are being developed for intratracheal administration.

 

LONDON--(BUSINESS WIRE)--May 14, 2018--Save big with Technavio this May!

 

LONDON--(BUSINESS WIRE)--May 14, 2018--Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all non-alcoholic beverages reports for the entire month.

 

LONDON--(BUSINESS WIRE)--May 14, 2018--OR

 

LONDON--(BUSINESS WIRE)--May 14, 2018--Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period.

 

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005756/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES BABY/MATERNITY RESEARCH CONSUMER SCIENCE GENERAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 05/14/2018 09:40 AM/DISC: 05/14/2018 09:40 AM

http://www.businesswire.com/news/home/20180514005756/en